Trials / No Longer Available
No Longer AvailableNCT01634230
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ocera Therapeutics, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.
Detailed description
This is an open-label study in patients diagnosed with ALF who are not responding to the institution's standards of care. Standard of care may include, but is not limited to, administration of N-acetylcysteine, lactulose, hypothermia therapy, and consideration for orthotopic liver transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OCR-002 | daily dose: 10 g infused over 24 hours |
Timeline
- First posted
- 2012-07-06
- Last updated
- 2021-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01634230. Inclusion in this directory is not an endorsement.